Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-026 | 1836-75-5 | Nitrofen | Rats | Osborne Mendel | Female | Dosed-Feed | Pancreas Acinar Cell | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| Yes | TR-196 | 87-29-6 | Cinnamyl anthranilate | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Positive | Positive | ADENOMA 1/47 3/47 7/49 | Neoplastic Lesions |
| Yes | TR-304 | 115-28-6 | Chlorendic acid | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 0/49 4/50 6/50 | Neoplastic Lesions |
| Yes | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 25/50 30/49 33/50 | Neoplastic Lesions |
| Yes | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 2/50 13/50 6/50 | Neoplastic Lesions |
| Yes | TR-334 | 121-88-0 | 2-Amino-5-nitrophenol | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 1/50 10/50 3/49 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 5/50 21/50 36/49 29/52 | Neoplastic Lesions |
| Yes | TR-458 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 3/50 2/49 3/50 10/50 OR CARCINOMA 0/50 0/49 0/50 1/50 COMBINED 3/50 2/49 3/50 11/50 | Neoplastic Lesions |
| Yes | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50 | Neoplastic Lesions |
| Yes | TR-526 | TEFDIOXINMIX | Toxic equivalency factor evaluation (Dioxin mixture) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/52 1/53 2/53 2/53 0/51 | May Have Been Related |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| Yes | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49 | May Have Been Related |
| Yes | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Some Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49 | May Have Been Related |
| Yes | TR-559 | 31508-00-6 | Toxic equivalency factor evaluation (PCB 118) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | Adenoma 0/52 0/52 0/52 2/52 3/52 1/47 0/49 adenoma or carcinoma 0/50 0/52 0/52 2/52 3/52 2/47 0/49 | May Have Been Related |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | Perinatal + Postweaning: acinar cell adenoma (7/50, 18/50, 30/50, 30/50); acinar cell adenocarcinoma (0/50, 2/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (7/50, 20/50, 30/50, 30/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | Postweaning: acinar cell adenoma (3/50, 28/50, 26/50, 32/50); acinar cell adenocarcinoma (0/50, 3/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (3/50, 29/50, 26/50, 32/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Some Evidence | Some Evidence | Perinatal + Postweaning: acinar cell adenoma (0/50, 0/50, 3/50); acinar cell adenocarcinoma (0/50, 0/50, 2/50); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 5/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Some Evidence | Some Evidence | Postweaning: acinar cell adenoma (0/50, 0/50, 1/49); acinar cell adenocarcinoma (0/50, 0/50, 1/49); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 2/49) | Neoplastic Lesions |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma (10/50, 7/49, 8/50, 36/50, 22/49); acinar carcinoma (0/50, 0/49, 0/50, 3/50, 1/49); acinar adenoma or carcinoma (combined) (10/50, 7/49, 8/50, 38/50, 22/49) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma or carcinoma (combined) (0/49, 0/50, 0/50, 2/50, 1/48) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma (1/49, 4/50, 5/50, 23/50, 30/50); acinar carcinoma (0/49, 1/50, 0/50, 1/50, 5/50); acinar adenoma or carcinoma (combined) (1/49, 5/50, 5/50, 23/50, 33/50) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma or carcinoma (combined) (0/50, 0/50, 0/50, 1/50, 2/47) | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/50 7/51 10/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/52 2/51 10/54 11/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/49 0/47 1/52 2/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 0/50 2/48 1/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 20/49 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/50 6/49 12/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 5/50 21/50 36/49 29/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 1/59 0/60 4/60 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 0/60 0/59 3/60 | Neoplastic Lesions |
| No | TR-334 | 121-88-0 | 2-Amino-5-nitrophenol | Mice | B6C3F1 | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-334 | 121-88-0 | 2-Amino-5-nitrophenol | Mice | B6C3F1 | Male | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-334 | 121-88-0 | 2-Amino-5-nitrophenol | Rats | F344/N | Female | Gavage | Clitoral Gland | No Evidence | Equivocal Evidence | ADENOMA 2/50 1/50 7/50 OR CARCINOMA 1/50 2/50 0/50 COMBINED 3/50 3/50 7/50 | May Have Been Related |
| Yes | TR-334 | 121-88-0 | 2-Amino-5-nitrophenol | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 1/50 10/50 3/49 | Neoplastic Lesions |
| No | TR-334 | 121-88-0 | 2-Amino-5-nitrophenol | Rats | F344/N | Male | Gavage | Preputial Gland | Some Evidence | Equivocal Evidence | ADENOMA 3/50 2/50 1/50 OR CARCINOMA 0/50 0/50 4/50 COMBINED 3/50 2/50 5/50 | May Have Been Related |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Mice | B6C3F1 | Male | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Female | Gavage | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 1/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 18/50 25/50 22/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/50 2/50 2/49 COMBINED 18/50 27/50 24/49 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 7/50 16/50 3/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Mice | B6C3F1 | Female | Gavage | Liver | Equivocal Evidence | Equivocal Evidence | ADENOMA 3/50 7/49 4/50 OR CARCINOMA 1/50 5/49 0/50 COMBINED 4/50 12/49 4/50 | Neoplastic Lesions |
| Yes | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 2/50 13/50 6/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Female | Gavage | Pituitary Gland | Some Evidence | Some Evidence | ADENOMA 15/49 24/50 25/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Preputial Gland | Some Evidence | Some Evidence | ADENOMA 0/50 4/50 4/50 OR CARCINOMA 1/50 2/50 1/50 COMBINED 1/50 6/50 5/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Female | Gavage | Liver | Positive | Positive | ADENOMA 2/50 3/50 12/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Liver | Positive | Positive | NEOPLASTIC NODULE 3/50 8/50 8/48 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Mammary Gland | Positive | Positive | FIBROADENOMA 15/50 21/50 18/50 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Positive | Positive | ADENOMA 1/47 3/47 7/49 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Pancreas Islet Cell | Positive | Positive | ADENOMA 0/50 6/49 2/47 CARCINOMA 0/50 1/49 0/47 COMBINED 0/50 7/49 2/47 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 0/50 1/50 3/50 OR FIBROSARCOMA 2/50 0/50 2/50 COMBINED 2/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 3/50 3/50 9/50 OR FIBROSARCOMA 0/50 3/50 3/50 COMBINED 3/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Female | Gavage | Vascular System (Unspecified) | Positive | Positive | HEMANGIOMA 0/50 1/50 2/50 OR HEMANGIOSARCOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-458 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Female | Dosed-Feed | Pancreas Acinar Cell | Equivocal Evidence | Equivocal Evidence | ADENOMA 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| Yes | TR-458 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 3/50 2/49 3/50 10/50 OR CARCINOMA 0/50 0/49 0/50 1/50 COMBINED 3/50 2/49 3/50 11/50 | Neoplastic Lesions |
| No | TR-458 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Female | Dosed-Feed | Urinary Bladder | Equivocal Evidence | Equivocal Evidence | TRANSITIONAL CELL PAPILLOMA 1/50 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-304 | 115-28-6 | Chlorendic acid | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-304 | 115-28-6 | Chlorendic acid | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/50 9/49 10/50; CARCINOMA 9/50 17/49 20/50 | Neoplastic Lesions |
| No | TR-304 | 115-28-6 | Chlorendic acid | Rats | F344/N | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 1/50 3/49 11/50; CARCINOMA 0/50 3/49 5/50 | Neoplastic Lesions |
| No | TR-304 | 115-28-6 | Chlorendic acid | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 2/50 21/50 23/50 | Neoplastic Lesions |
| No | TR-304 | 115-28-6 | Chlorendic acid | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Equivocal Evidence | ADENOMA 0/50 3/50 5/50 | May Have Been Related |
| Yes | TR-304 | 115-28-6 | Chlorendic acid | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 0/49 4/50 6/50 | Neoplastic Lesions |
| No | TR-304 | 115-28-6 | Chlorendic acid | Rats | F344/N | Male | Dosed-Feed | Preputial Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 1/50 8/50 4/50 | May Have Been Related |
| No | TR-196 | 87-29-6 | Cinnamyl anthranilate | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-196 | 87-29-6 | Cinnamyl anthranilate | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Positive | Positive | ADENOMA OR ADENOCARCINOMA | Neoplastic Lesions |
| No | TR-196 | 87-29-6 | Cinnamyl anthranilate | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-196 | 87-29-6 | Cinnamyl anthranilate | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-196 | 87-29-6 | Cinnamyl anthranilate | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | May Have Been Related | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | May Have Been Related | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (0/50, 0/50, 1/50, 1/50, 13/49); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 2/49); hepatocellular adenoma or carcinoma (combined) (0/50, 0/50, 1/50, 1/50, 14/49) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (1/49, 0/50, 5/50, 9/50, 5/48); hepatocellular carcinoma (0/49, 0/50, 0/50, 0/50, 8/48); hepatocellular adenoma or carcinoma (combined) (1/49, 0/50, 5/50, 9/50, 13/48) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (0/50, 1/49, 0/50, 3/50, 8/49); hepatocellular carcinoma (1/50, 0/49, 0/50, 0/50, 3/49); hepatocellular adenoma or carcinoma (combined) (1/50, 1/49, 0/50, 3/50, 11/49) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (0/50, 2/50, 0/50, 1/50, 6/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 6/50); hepatocellular adenoma or carcinoma (combined) (0/50, 2/50, 0/50, 1/50, 12/50) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma or carcinoma (combined) (0/50, 0/50, 0/50, 1/50, 2/47) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma or carcinoma (combined) (0/49, 0/50, 0/50, 2/50, 1/48) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma (10/50, 7/49, 8/50, 36/50, 22/49); acinar carcinoma (0/50, 0/49, 0/50, 3/50, 1/49); acinar adenoma or carcinoma (combined) (10/50, 7/49, 8/50, 38/50, 22/49) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma (1/49, 4/50, 5/50, 23/50, 30/50); acinar carcinoma (0/49, 1/50, 0/50, 1/50, 5/50); acinar adenoma or carcinoma (combined) (1/49, 5/50, 5/50, 23/50, 33/50) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Testis | Clear Evidence | interstitial cell, adenoma (7/50, 3/50, 3/50, 6/50, 15/50) | May Have Been Related | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Uterus | Clear Evidence | adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (3/50, 1/50, 1/50, 3/50, 7/50) | May Have Been Related | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Uterus | Clear Evidence | adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (2/50, 4/50, 1/50, 6/50, 13/50) | Neoplastic Lesions | |
| No | TR-342 | 62-73-7 | Dichlorvos | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 5/49 6/49 18/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Mice | B6C3F1 | Male | Gavage | Forestomach | Some Evidence | Some Evidence | SQUAMOUS CELL PAPILLOMA 1/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 11/50 20/50 21/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Female | Gavage | Mammary Gland | Equivocal Evidence | Equivocal Evidence | FIBROADENOMA 9/50 19/50 16/50 OR ADENOMA 0/50 0/50 1/50 COMBINED 9/50 19/50 17/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Female | Gavage | Pancreas Acinar Cell | Equivocal Evidence | Equivocal Evidence | ADENOMA 2/50 3/47 6/50 | Neoplastic Lesions |
| Yes | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 25/50 30/49 33/50 | Neoplastic Lesions |
| No | TR-026 | 1836-75-5 | Nitrofen | Rats | Osborne Mendel | Male | Dosed-Feed | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-026 | 1836-75-5 | Nitrofen | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | HEPATOCELLULAR CARCINOMA | Neoplastic Lesions |
| No | TR-026 | 1836-75-5 | Nitrofen | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | HEPATOCELLULAR CARCINOMA | Neoplastic Lesions |
| Yes | TR-026 | 1836-75-5 | Nitrofen | Rats | Osborne Mendel | Female | Dosed-Feed | Pancreas Acinar Cell | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-026 | 1836-75-5 | Nitrofen | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Liver) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-026 | 1836-75-5 | Nitrofen | Mice | B6C3F1 | Male | Dosed-Feed | Vascular System (Liver) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Unspecified | Clear Evidence | Not applicable | Not applicable | |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Unspecified | Some Evidence | Not applicable | Not applicable | |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Liver | Some Evidence | Equivocal Evidence | Postweaning: hepatocellular carcinoma (1/50, 1/50, 3/49) | May Have Been Related |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Liver | Some Evidence | Equivocal Evidence | Perinatal + Postweaning: hepatocellular carcinoma (1/50, 0/50, 4/50) | May Have Been Related |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | Perinatal + Postweaning: hepatocellular adenoma (0/50, 1/50, 5/50, 10/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 4/50); hepatocellular adenoma or carcinoma (0/50, 1/50, 5/50, 12/50) | Neoplastic Lesions |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | Postweaning: hepatocellular adenoma (0/50, 0/50, 7/50, 11/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50); hepatocellular adenoma or carcinoma (0/50, 0/50, 7/50,11/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | Postweaning: acinar cell adenoma (3/50, 28/50, 26/50, 32/50); acinar cell adenocarcinoma (0/50, 3/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (3/50, 29/50, 26/50, 32/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | Perinatal + Postweaning: acinar cell adenoma (7/50, 18/50, 30/50, 30/50); acinar cell adenocarcinoma (0/50, 2/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (7/50, 20/50, 30/50, 30/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Some Evidence | Some Evidence | Perinatal + Postweaning: acinar cell adenoma (0/50, 0/50, 3/50); acinar cell adenocarcinoma (0/50, 0/50, 2/50); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 5/50) | Neoplastic Lesions |
| Yes | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Some Evidence | Some Evidence | Postweaning: acinar cell adenoma (0/50, 0/50, 1/49); acinar cell adenocarcinoma (0/50, 0/50, 1/49); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 2/49) | Neoplastic Lesions |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Uterus | Some Evidence | Equivocal Evidence | Perinatal + Postweaning: adenocarcinoma (1/50, 3/50, 5/50) | May Have Been Related |
| No | TR-598 | 335-67-1 | Perfluorooctanoic acid (PFOA) | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Uterus | Some Evidence | Equivocal Evidence | Postweaning: adenocarcinoma (1/50, 5/50, 8/50) | May Have Been Related |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | CHOLANGIOCARCINOMA 0/53 0/53 1/52 9/52 30/51 HEPATOCHOLANGIOMA 0/53 0/53 0/52 2/52 6/51 ADENOMA 0/53 0/53 3/52 5/52 27/51 | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/52 1/53 11/52 | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA (GINGIVAL) 0/53 0/53 2/53 5/53 9/53 | Neoplastic Lesions |
| Yes | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50 | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53 | May Have Been Related |
| No | TR-526 | TEFDIOXINMIX | Toxic equivalency factor evaluation (Dioxin mixture) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/53 1/53 1/53 1/53 11/51 OR CHOLANGIOCARCINOMA 0/53 0/53 2/53 7/53 9/51 | Neoplastic Lesions |
| No | TR-526 | TEFDIOXINMIX | Toxic equivalency factor evaluation (Dioxin mixture) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/53 2/53 20/53 | Neoplastic Lesions |
| Yes | TR-526 | TEFDIOXINMIX | Toxic equivalency factor evaluation (Dioxin mixture) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/52 1/53 2/53 2/53 0/51 | May Have Been Related |
| No | TR-559 | 31508-00-6 | Toxic equivalency factor evaluation (PCB 118) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | Cholangiocarcinoma 0/52 0/51 0/52 0/52 3/52 36/49 29/49 adenoma 0/52 1/51 1/52 4/52 12/52 24/49 1/49 hepatocholangioma 0/52 0/51 0/52 0/52 0/52 4/49 0/49 | Neoplastic Lesions |
| No | TR-559 | 31508-00-6 | Toxic equivalency factor evaluation (PCB 118) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | Cystic keratinizing epithelioma 0/51 0/52 0/52 0/52 0/52 20/50 0/50 | Neoplastic Lesions |
| Yes | TR-559 | 31508-00-6 | Toxic equivalency factor evaluation (PCB 118) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | Adenoma 0/52 0/52 0/52 2/52 3/52 1/47 0/49 adenoma or carcinoma 0/50 0/52 0/52 2/52 3/52 2/47 0/49 | May Have Been Related |
| No | TR-559 | 31508-00-6 | Toxic equivalency factor evaluation (PCB 118) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus | Clear Evidence | Equivocal Evidence | Squamous cell carcinoma: 0/52 0/52 3/52 1/52 1/52 0/52 1/50 | May Have Been Related |
| No | TR-559 | 31508-00-6 | Toxic equivalency factor evaluation (PCB 118) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus | Clear Evidence | Clear Evidence | Carcinoma 2/52 2/52 1/52 3/52 4/52 3/52 11/50 | Neoplastic Lesions |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Some Evidence | Some Evidence | ADENOMA 1/53 0/53 1/53 0/52 2/53 4/53 1/50 OR CHOLANGIOCARCINOMA 0/53 0/53 0/53 1/52 1/53 2/53 0/50 | Neoplastic Lesions |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Some Evidence | Equivocal Evidence | CYSTIC KERATINIZING EPITHELIOMA (MULTIPLE) 0/53 0/53 0/53 0/53 0/53 1/52 0/50 | May Have Been Related |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Some Evidence | Some Evidence | (ORAL MUCOSA) GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 2/53 1/53 0/53 1/53 3/53 3/50 | Neoplastic Lesions |
| Yes | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Some Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49 | May Have Been Related |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Some Evidence | Equivocal Evidence | CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50 | May Have Been Related |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Equivocal Evidence | HEPATOCHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 2/53 0/50 OR CHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 0/53 1/50 | May Have Been Related |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/53 0/54 0/53 0/53 1/53 13/53 2/50 OR CHOLANGIOCARCINOMA 0/53 0/54 0/53 1/53 4/53 25/53 2/50 | Neoplastic Lesions |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | CYSTIC KERATINIZING EPITHELIOMA 0/53 0/54 0/53 0/52 0/53 9/52 0/50 | Neoplastic Lesions |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | GINGIVAL SQAMOUS CELL CARCINOMA (ORAL MUCOSA) 1/53 2/54 1/53 0/53 4/53 10/53 5/50 | Neoplastic Lesions |
| Yes | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49 | May Have Been Related |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50 | Neoplastic Lesions |